Information Provided By:
Fly News Breaks for November 6, 2019
Nov 6, 2019 | 15:07 EDT
JMP Securities analyst Liisa Bayko reiterated an Outperform rating and $25 price target on ProQR Therapeutics after the company reported Q3 results. The analyst noted that the company ended the quarter with ~$137M in pro forma cash, which management guided to as sufficient runway into 2022. Bayko sees the next major catalyst for ProQR being proof-of-concept data for QR-421a in Usher syndrome in Q1 of 2020, adding this this is "a significant opportunity... which we estimate could reach ~$1B."
News For PRQR From the Last 2 Days
There are no results for your query PRQR